|
Market Closed -
London S.E.
09:05:05 16/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 1,865.50 GBX | +0.62% |
|
+3.44% | +2.25% |
| 07:25pm | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 12:30pm | UK inflation rises; Barratt cuts completions outlook | AN |
| Market Cap | 7.43TCr 9.99TCr 8.66TCr 8.18TCr 14TCr 9,58400Cr 14TCr 98TCr 38TCr 4,86100Cr 38TCr 37TCr 15,49500Cr | P/E 2026 * |
14.2x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 9.5TCr 13TCr 11TCr 10TCr 18TCr 12,25200Cr 18TCr 1,24900Cr 48TCr 6,21400Cr 48TCr 47TCr 19,80800Cr | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.6x |
| Free-Float |
92.75% | Yield 2026 * |
3.75% | Yield 2027 * | 4.04% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
OTC Markets
| GLAXF | Delayed | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Börse Stuttgart
| GS71 | Delayed |
Last Transcript: GSK plc
| 1 day | +0.58% | ||
| 1 week | +3.44% | ||
| Current month | +0.65% | ||
| 1 month | +0.76% | ||
| 3 months | -4.33% | ||
| 6 months | -7.92% | ||
| Current year | +2.25% |
| 1 week | 1,770 |  | 1,883.5 |
| 1 month | 1,770 | | 1,937 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,455 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
James Ford
CMP | Compliance Officer | - | 01/08/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 67 | 01/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 09/09/26 | Free | Compliance Officer | 7 | 0.0000% | ||
| 09/09/26 | Buy | Executive/Senior Manager | 7 | 0.0000% | ||
| 09/09/26 | Free | Executive/Senior Manager | 7 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.62% | +3.44% | +27.51% | +23.92% | 10TCr | |
| -0.12% | +0.96% | +48.43% | +98.68% | 1,01300Cr | |
| +0.24% | +0.27% | +51.76% | +64.83% | 64TCr | |
| -0.30% | +4.46% | +21.20% | +70.26% | 46TCr | |
| +0.53% | +4.26% | +40.29% | +40.53% | 35TCr | |
| +0.39% | +2.35% | +17.96% | +24.19% | 26TCr | |
| +0.17% | +4.17% | +6.96% | +13.12% | 25TCr | |
| -0.02% | -3.90% | +37.69% | +42.89% | 20TCr | |
| -1.20% | -5.64% | -24.09% | -58.09% | 19TCr | |
| +0.62% | +1.19% | +32.95% | +94.91% | 18TCr | |
| Average | +0.05% | -0.66% | +26.07% | +41.53% | 36.64TCr | |
| Weighted average by Cap. | +0.02% | +0.10% | +34.05% | +58.87% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 4.56TCr 3.95TCr 3.74TCr 6.36TCr 4,37800Cr 6.4TCr 45TCr 17TCr 2,22000Cr 17TCr 17TCr 7,07800Cr | 3.55TCr 4.77TCr 4.14TCr 3.91TCr 6.65TCr 4,58000Cr 6.69TCr 47TCr 18TCr 2,32300Cr 18TCr 18TCr 7,40500Cr |
| Net income | 534.79Cr 719.19Cr 623.25Cr 589.07Cr 1TCr 69TCr 1.01TCr 7.03TCr 2.72TCr 35TCr 2.7TCr 2.64TCr 1,11500Cr | 628.41Cr 845.09Cr 732.36Cr 692.2Cr 1.18TCr 81TCr 1.18TCr 8.26TCr 3.19TCr 41TCr 3.17TCr 3.1TCr 1,31100Cr |
| Net Debt | 2.07TCr 2.78TCr 2.41TCr 2.28TCr 3.88TCr 2,66800Cr 3.9TCr 27TCr 11TCr 1,35300Cr 10TCr 10TCr 4,31300Cr | 1.8TCr 2.42TCr 2.09TCr 1.98TCr 3.37TCr 2,31800Cr 3.39TCr 24TCr 9.13TCr 1,17600Cr 9.08TCr 8.88TCr 3,74800Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/26/16 | GBX 1,865.50 | +0.62% | 37,84,583 |
| 15/26/15 | GBX 1,854.00 | -0.03% | 49,02,189 |
| 14/26/14 | GBX 1,854.50 | +4.74% | 43,65,927 |
| 11/26/11 | GBX 1,770.50 | -0.28% | 39,34,440 |
| 10/26/10 | GBX 1,775.50 | -1.55% | 30,18,902 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
